Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Biocon might spin out its CRO after taking it public

Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.

Lupin antibiotic products banned by Brazil

Lupin, which has been expanding its manufacturing and marketing footprint internationally via M&A, moved on Brazil in May with the acquisition of generics and OTC maker Medquímica Indústria Farmacêutica. But new markets mean new regulations, and the Indian company has been tripped by some issues that led Brazil to ban some of Lupin's antibiotic products.

Chinese staffer key to negotiating deal to bolster FDA staff in China

Vice President Joe Biden weighed in with the Chinese on FDA's efforts to negotiate an agreement to bump up its inspection staff in the country. So did former FDA Commissioner Margaret Hamburg. But it is locally employed FDA staffer Lixia Wang who has won the prize, in part for her efforts to help seal the deal.

India's Lupin gets Russian production site in deal for Biocom

While recent problems in Russia's economy have thrown some deals off course, Western drugmakers in the last several years have built or bought production capacity in Russia to tap what has been seen as an important emerging market. India's Lupin jumped into that market, picking up a company that will give it a production toehold there.

GSK's ViiV turns to Chinese company for cheap supply of Tivicay API

The HIV-oriented joint venture of Pfizer, GlaxoSmithKline and Japan's Shionogi is turning to a Chinese manufacturer for a cheap supply of dolutegravir, the active ingredient in its Tivicay. The deal is seen as a way to cut the cost in China and some other developing countries of the JV's newest HIV fighter.

GSK doubles down on Singapore continuous processing plant

Several years ago, GlaxoSmithKline committed $50 million to set up an antibiotics facility in Singapore to do continuous processing, a radically different manufacturing approach that has a much smaller footprint, and so much lower operating costs and less environmental impact, than traditional batch processing. The drugmaker now says it is ready to embark on a £38 million expansion there.

Move over, India--China can make WHO-approved vaccines, too

China's growing vaccine industry scored again on Friday when the World Health Organization announced that it had approved a Chinese flu vaccine.

Pfizer supplements its China production with $90M plant

Pfizer has broken ground on a $90 million facility that is being built in Suzhou, China, it announced Monday. The additional capacity is needed as demand for its supplements grows in the Asia-Pacific region, particularly in China.

South African regulator eases API oversight rules in face of shortages

South Africa, facing a growing number of drug shortages, particularly of penicillin, is changing its inspection requirements in a move that will make it easier for drugmakers to switch suppliers of active pharmaceutical ingredients (APIs).

AstraZeneca's manufacturing gets another boost with $125M Africa plant

Just weeks after AstraZeneca said it would build a new facility in Sweden where it intends to fill and package biologics, the U.K. drugmaker said it was doing something more traditional in Algeria. Through a joint venture there, it will build a $125 million small-molecule plant.